Matthew J Dean
Overview
Explore the profile of Matthew J Dean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thylur Puttalingaiah R, Dean M, Zheng L, Philbrook P, Wyczechowska D, Kayes T, et al.
Cells
. 2024 Oct;
13(20.
PMID: 39451254
Potassium ions (K) are critical electrolytes that regulate multiple functions in immune cells. Recent studies have shown that the elevated concentration of extracellular potassium in the tumor interstitial fluid limits...
2.
Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer
Russo A, Yang Z, Heyrman G, Cain B, Lopez Carrero A, Isenberg B, et al.
Cancer Lett
. 2022 Jun;
543():215779.
PMID: 35697329
High grade serous ovarian cancers (HGSOC) predominantly arise in the fallopian tube epithelium (FTE) and colonize the ovary first, before further metastasis to the peritoneum. Ovarian cancer risk is directly...
3.
Dean M, Ochoa J, Sanchez-Pino M, Zabaleta J, Garai J, Del Valle L, et al.
Front Immunol
. 2021 Aug;
12:695972.
PMID: 34341659
COVID-19 ranges from asymptomatic in 35% of cases to severe in 20% of patients. Differences in the type and degree of inflammation appear to determine the severity of the disease....
4.
Russo A, Colina J, Moy J, Baligod S, Czarnecki A, Varughese P, et al.
Cell Death Dis
. 2021 Apr;
12(4):375.
PMID: 33828085
High-grade serous ovarian cancer (HGSOC) is the most lethal gynecological malignancy that is primarily detected at the metastatic stage. Most HGSOC originates from the fallopian tube epithelium (FTE) and metastasizes...
5.
Dean M, Ochoa J, Sanchez-Pino M, Zabaleta J, Garai J, Del Valle L, et al.
medRxiv
. 2021 Apr;
PMID: 33791717
COVID-19 ranges from asymptomatic in 35% of cases to severe in 20% of patients. Differences in the type and degree of inflammation appear to determine the severity of the disease....
6.
Tso F, Lidenge S, Poppe L, Pena P, Privatt S, Bennett S, et al.
PLoS One
. 2021 Mar;
16(3):e0247640.
PMID: 33661923
Background: Neutralizing-antibody (nAb) is the major focus of most ongoing COVID-19 vaccine trials. However, nAb response against SARS-CoV-2, when present, decays rapidly. Given the myriad roles of antibodies in immune...
7.
Sanchez-Pino M, Dean M, Ochoa A
Cell Immunol
. 2021 Feb;
362:104302.
PMID: 33592540
MDSC are a heterogeneous population of immature myeloid cells that are released by biological stress such as tissue damage and inflammation. Conventionally, MDSC are known for their detrimental role in...
8.
Ghonim M, Ibba S, Tarhuni A, Errami Y, Luu H, Dean M, et al.
J Immunother Cancer
. 2021 Jan;
9(1).
PMID: 33495297
Background: Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions. The benefits of...
9.
Al-Khami A, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, et al.
Oncoimmunology
. 2017 Nov;
6(10):e1344804.
PMID: 29123954
Myeloid-derived suppressor cells (MDSC) promote tumor growth by blocking anti-tumor T cell responses. Recent reports show that MDSC increase fatty acid uptake and fatty acid oxidation (FAO) to support their...